by Mark Curtis | Apr 30, 2014
. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is...
by Paul Krzyzanowski | Apr 22, 2014
> If you’ve stayed current with the STAP cell fiasco you know it’s been a wild ride. STAP cells, or Stimulus-Triggered Acquisition of Pluripotency cells, caught the imagination of many in late January through their sheer simplicity: You hit cells with a shock of...
by David Kent | Apr 15, 2014
> In February this year, the biggest stem cell trial for heart attack patients was begun and will involve over 3000 patients from 11 different countries in Europe. The BAMI trial (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on...
by Alessandra Pasut | Apr 2, 2014
Editor’s note: Some of the links included are Italian language sources The case involving Stamina Foundation and the legitimacy of its stem cell treatments has been one of the most discussed and controversial issues in the international stem cell policy scene....
by Sara M. Nolte | Mar 4, 2014
> A little while ago, I wrote a post about the BRCA1 gene and its role in breast cancer, and suggested that Angelina Jolie’s mastectomy reveal was a missed opportunity to provide information about hereditary breast cancer. I have since wondered what did we get out...
by Sara M. Nolte | Jan 15, 2014
> I have recently been transitioning from “basic” science research to science communication. Why? Because there is a great disparity in what the public, policy makers, and even clinicians, know and think about research, and what the researchers know. I believe as...
Comments